text
"[""\n1. 요약재무정보\n가. 요약연결재무정보\n\xa0 \xa0 \xa0 ( 단위 : 천원 )\n구분\n제 52 기 반기\n제 51 기\n제 50 기\n연결재무상태표\n2022. 6월말\n2021. 12월말\n2020. 12월말\n\xa0[유동자산]\n33,439,126\n76,863,062\n20,426,044\n\xa0ㆍ현금및현금성자산\n10,206,519\n9,186,408\n2,421,594\n\xa0ㆍ단기금융상품\n50,000\n91,943\n-\n\xa0ㆍ매출채권\n15,595,272\n20,859,343\n14,487,472\n\xa0ㆍ기타자산\n4,912,826\n4,405,358\n3,277,070\n\xa0ㆍ매각예정비유동자산\n-\n39,906,534\n-\n\xa0ㆍ재고자산\n2,674,509\n2,413,475\n239,908\n\xa0[비유동자산]\n63,603,960\n39,563,751\n48,170,596\n\xa0ㆍ금융자산\n11,147,351\n3,412,954\n2,466,679\n\xa0ㆍ종속기업및관계기업투자\n-\n-\n42,868,381\n\xa0ㆍ유형자산\n22,945,178\n19,622,969\n71,965\n\xa0ㆍ사용권자산\n2,578,502\n1,930,936\n908,620\n\xa0ㆍ무형자산\n10,759,681\n11,204,427\n726,936\n\xa0ㆍ투자부동산\n13,533,787\n-\n-\n\xa0ㆍ장기매출채권\n171,644\n133,463\n218,609\n\xa0ㆍ기타자산\n2,467,815\n3,259,002\n909,406\n자 \xa0산 \xa0총 \xa0계\n97,043,086\n116,426,813\n68,596,640\n\xa0[유동부채]\n46,994,973\n65,942,789\n45,070,943\n\xa0[비유동부채]\n7,213,419\n5,943,255\n3,851,122\n부 채 총 계\n54,208,392\n71,886,044\n48,922,065\n\xa0[지배기업 소유지지분]\n30,545,151\n31,144,703\n19,674,575\n\xa0ㆍ자본금\n15,624,678\n15,560,554\n12,508,293\n\xa0ㆍ자본잉여금\n52,239,055\n53,286,363\n35,270,580\n\xa0ㆍ기타자본항목\n1,428,920\n1,428,920\n1,428,920\n\xa0ㆍ기타포괄손익누계액\n(4,009,962)\n(4,007,401)\n(1,635,666)\n\xa0ㆍ이익잉여금\n(34,737,540)\n(35,123,732)\n(27,897,552)\n\xa0[비지배지분]\n12,289,543\n13,396,065\n-\n자 본 총 계\n42,834,694\n44,540,769\n19,674,575\n종속기업및 관계기업 투자주식의 평가방법\n원가법\n지분법\n지분법\n연결손익계산서\n22.01.01~06.30\n'21.01.01~12.31\n'20.01.01~12.31\n\xa0매출액\n65,381,094\n75,724,705\n72,469,645\n\xa0영업손익\n2,126,895\n(6,633,228)\n(1,999,554)\n\xa0연결계속영업당기순이익\n1,128,155\n(7,010,942)\n(10,311,445)\nㆍ지배기업소유주지분손익\n370,335\n(7,180,518)\n(10,311,445)\nㆍ비지배기업소유주지분손익\n757,820\n169,576\n-\n\xa0연결중단영업당기순이익\n49,885\n(911,372)\n9,184,574\n\xa0당기순손익\n1,178,040\n(7,922,314)\n(1,126,871)\n\xa0주당순손익(원)\n13\n(265)\n(120)\n\xa0연결에포함된회사수\n1개\n1개\n-\n※ 상기 요약 재무정보는 한국 채택국제회계기준(K-IFRS)에 따라 작성되었습니다.※ 2019년 1월 1일을 최초적용일로 하여 K-IFRS 제1116호를 최초 적용하였습니다.\n나. 연결재무제표의 연결에 포함된 회사\n종속기업명\n소유지분율\n소재지\n결산월\n업종\n셀론텍(주)\n57.5%\n한국\n12월\n바이오콜라겐 기반 치료재료 생산 및 판매\n다. 요약재무정보(별도)\n\xa0 \xa0 \xa0 ( 단위 : 천원 )\n구분\n제 52 기 반기\n제 51 기\n제 50 기\n재무상태표\n2022. 06월말\n2021. 12월말\n2020. 12월말\n\xa0[유동자산]\n28,024,773\n71,364,365\n20,426,044\n\xa0ㆍ현금및현금성자산\n6,543,876\n7,711,622\n2,421,593\n\xa0ㆍ매출채권\n15,295,791\n20,450,332\n14,487,472\n\xa0ㆍ기타자산\n5,807,505\n3,157,130\n3,277,071\n\xa0ㆍ매각예정비유동자산\n-\n39,906,534\n-\n\xa0ㆍ재고자산\n377,601\n138,747\n239,908\n\xa0[비유동자산]\n51,112,099\n28,233,309\n48,170,596\n\xa0ㆍ금융자산\n11,147,251\n3,412,954\n2,466,679\n\xa0ㆍ종속기업및관계기업투자\n18,623,460\n17,136,000\n42,868,381\n\xa0ㆍ유형자산\n370,157\n42,588\n71,965\n\xa0ㆍ사용권자산\n944,866\n265,543\n908,620\n\xa0ㆍ무형자산\n5,485,015\n5,734,757\n726,936\n\xa0ㆍ투자부동산\n13,533,787\n-\n-\n\xa0ㆍ장기매출채권\n171,644\n133,463\n218,609\n\xa0ㆍ기타자산\n835,919\n1,508,004\n909,406\n자 \xa0산 \xa0총 \xa0계\n79,136,872\n99,597,674\n68,596,640\n\xa0[유동부채]\n44,021,883\n64,183,602\n45,070,943\n\xa0[비유동부채]\n2,104,431\n911,128\n3,851,122\n부 채 총 계\n46,126,314\n65,094,730\n48,922,065\n\xa0ㆍ자본금\n15,624,678\n15,560,554\n12,508,293\n\xa0ㆍ자본잉여금\n49,692,842\n51,132,267\n33,093,573\n\xa0ㆍ기타포괄손익누계액\n(4,009,962)\n(4,007,401)\n(1,635,666)\n\xa0ㆍ이익잉여금\n(28,297,000)\n(28,182,476)\n(24,291,625)\n자 본 총 계\n33,010,558\n34,502,944\n19,674,575\n종속기업 투자주식의 평가방법\n원가법\n원가법\n원가법\n관계기업 투자주식의 평가방법\n-\n지분법\n지분법\n손익계산서\n'22.01.01~06.30\n'21.01.01~12.31\n'20.01.01~12.31\n\xa0매출액\n61,637,801\n80,226,517\n72,469,645\n\xa0영업손익\n666,292\n(4,012,277)\n(1,999,555)\n\xa0당기순손익\n(114,523)\n(4,457,200)\n(10,136,416)\n\xa0주당순손익(원)\n(4)\n(155)\n(405)\n※ 상기 요약 재무정보는 한국 채택국제회계기준(K-IFRS)에 따라 작성되었습니다.※ 2019년 1월 1일을 최초적용일로 하여 K-IFRS 제1116호를 최초 적용하였습니다.\n""]"
